

CLAIMS:

1. An immunoconjugate comprising an antibody covalently attached to one or more 8-amido-2-aminobenzazepine moieties by a linker, and having Formula I:




or a pharmaceutically acceptable salt thereof,

wherein:

Ab is the antibody;

p is an integer from 1 to 8;

8AmBza is the 8-amido-2-aminobenzazepine moiety having the formula:



y is 0 or 1;

Het is selected from the group consisting of heterocyclyl, heterocyclldiyl, heteroaryl, and heteroaryldiyl;

R^a is H or forms Het with the nitrogen atom it is bound to;

R¹, R², R³, and R⁴ are independently selected from the group consisting of H, C₁-C₁₂ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₂ carbocyclyl, C₆-C₂₀ aryl, C₂-C₉ heterocyclyl, and C₁-C₂₀ heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally substituted with one or more groups selected from:

- (C₁-C₁₂ alkylldiyl)-N(R⁵)-*;
- (C₁-C₁₂ alkylldiyl)-N(R⁵)₂;
- (C₁-C₁₂ alkylldiyl)-OR⁵;
- (C₃-C₁₂ carbocyclyl);
- (C₃-C₁₂ carbocyclyl)-*;
- (C₃-C₁₂ carbocyclyl)-(C₁-C₁₂ alkylldiyl)-NR⁵-*;
- (C₃-C₁₂ carbocyclyl)-(C₁-C₁₂ alkylldiyl)-N(R⁵)₂;
- (C₃-C₁₂ carbocyclyl)-NR⁵-C(=NR⁵)NR⁵-*;
- (C₆-C₂₀ aryl);

$-(C_6-C_{20} \text{ aryl})-^*$;
 $-(C_6-C_{20} \text{ aryl}diyl)-N(R^5)-^*$;
 $-(C_6-C_{20} \text{ aryl}diyl)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)-^*$;
 $-(C_6-C_{20} \text{ aryl}diyl)-(C_1-C_{12} \text{ alkyl}diyl)-(C_2-C_{20} \text{ heterocycl}diyl)-^*$;
 $-(C_6-C_{20} \text{ aryl}diyl)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)_2$;
 $-(C_6-C_{20} \text{ aryl}diyl)-(C_1-C_{12} \text{ alkyl}diyl)-NR^5-C(=NR^{5a})N(R^5)-^*$;
 $-(C_2-C_{20} \text{ heterocycl}yl)$;
 $-(C_2-C_{20} \text{ heterocycl}yl)-^*$;
 $-(C_2-C_9 \text{ heterocycl}yl)-(C_1-C_{12} \text{ alkyl}diyl)-NR^5-^*$;
 $-(C_2-C_9 \text{ heterocycl}yl)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)_2$;
 $-(C_2-C_9 \text{ heterocycl}yl)-NR^5-C(=NR^{5a})NR^5-^*$;
 $-(C_1-C_{20} \text{ heteroaryl})$;
 $-(C_1-C_{20} \text{ heteroaryl})-^*$;
 $-(C_1-C_{20} \text{ heteroaryl})-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)-^*$;
 $-(C_1-C_{20} \text{ heteroaryl})-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)_2$;
 $-(C_1-C_{20} \text{ heteroaryl})-NR^5-C(=NR^{5a})N(R^5)-^*$;
 $-C(=O)-^*$;
 $-C(=O)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)-^*$;
 $-C(=O)-(C_2-C_{20} \text{ heterocycl}diyl)-^*$;
 $-C(=O)N(R^5)_2$;
 $-C(=O)N(R^5)-^*$;
 $-C(=O)N(R^5)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)C(=O)R^5$;
 $-C(=O)N(R^5)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)C(=O)N(R^5)_2$;
 $-C(=O)NR^5-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)CO_2R^5$;
 $-C(=O)NR^5-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)C(=NR^{5a})N(R^5)_2$;
 $-C(=O)NR^5-(C_1-C_{12} \text{ alkyl}diyl)-NR^5C(=NR^{5a})R^5$;
 $-C(=O)NR^5-(C_1-C_8 \text{ alkyl}diyl)-NR^5(C_2-C_5 \text{ heteroaryl})$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroaryl}diyl)-N(R^5)-^*$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroaryl}diyl)-^*$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroaryl}diyl)-(C_1-C_{12} \text{ alkyl}diyl)-N(R^5)_2$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroaryl}diyl)-(C_2-C_{20} \text{ heterocycl}diyl)-C(=O)NR^5-(C_1-C_{12} \text{ alkyl}diyl)-NR^5-^*$;
 $-N(R^5)_2$;

$-N(R^5)-*$;
 $-N(R^5)C(=O)R^5$;
 $-N(R^5)C(=O)-*$;
 $-N(R^5)C(=O)N(R^5)_2$;
 $-N(R^5)C(=O)N(R^5)-*$;
 $-N(R^5)CO_2R^5$;
 $-NR^5C(=NR^{5a})N(R^5)_2$;
 $-NR^5C(=NR^{5a})N(R^5)-*$;
 $-NR^5C(=NR^{5a})R^5$;
 $-N(R^5)-(C_2-C_5 \text{ heteroaryl})$;
 $-O-(C_1-C_{12} \text{ alkyl})$;
 $-O-(C_1-C_{12} \text{ alkylidyl})-N(R^5)_2$;
 $-O-(C_1-C_{12} \text{ alkylidyl})-N(R^5)-*$;
 $-S(=O)_2-(C_2-C_{20} \text{ heterocyclyldiyl})-*$;
 $-S(=O)_2-(C_2-C_{20} \text{ heterocyclyldiyl})-(C_1-C_{12} \text{ alkylidyl})-N(R^5)_2$;
 $-S(=O)_2-(C_2-C_{20} \text{ heterocyclyldiyl})-(C_1-C_{12} \text{ alkylidyl})-NR^5-*$; and
 $-S(=O)_2-(C_2-C_{20} \text{ heterocyclyldiyl})-(C_1-C_{12} \text{ alkylidyl})-OH$;
 or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1 , X^2 , X^3 , and X^4 are independently selected from the group consisting of a bond, $C(=O)$, $C(=O)N(R^5)$, O , $N(R^5)$, S , $S(O)_2$, and $S(O)_2N(R^5)$;


R^5 is selected from the group consisting of H , C_6-C_{20} aryl, C_6-C_{20} arylidyl, C_1-C_{12} alkyl, and C_1-C_{12} alkylidyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of C_6-C_{20} aryl and C_1-C_{20} heteroaryl;

where the asterisk $*$ indicates the attachment site of L , and where one of R^1 , R^2 , R^3 and R^4 is attached to L ;


L is the linker selected from the group consisting of:

$-C(=O)-(PEG)-C(=O)-(PEP)-$;
 $-C(=O)-(PEG)-NR^5-$;
 $-C(=O)-(PEG)-NR^5-(PEG)-C(=O)-(PEP)-$;
 $-C(=O)-(PEG)-N^+(R^5)_2-(PEG)-C(=O)-(PEP)-$;
 $-C(=O)-(PEG)-C(=O)-$;
 $-C(=O)-(PEG)-NR^5CH(AA_1)C(=O)-(PEG)-C(=O)-(PEP)-$;
 $-C(=O)-(PEG)-SS-(C_1-C_{12} \text{ alkylidyl})-OC(=O)-$;




PEG has the formula: $-(\text{CH}_2\text{CH}_2\text{O})_n-(\text{CH}_2)_m-$; m is an integer from 1 to 5, and n is an integer from 2 to 50;

PEP has the formula:




where AA₁ and AA₂ are independently selected from an amino acid side chain, or AA₁ or AA₂ and an adjacent nitrogen atom form a 5-membered ring proline amino acid, and the wavy line indicates a point of attachment and;

R⁶ is selected from the group consisting of C₆-C₂₀ arylidiyl and C₁-C₂₀ heteroaryldiyl, substituted with -CH₂O-C(=O)- and optionally with:




; and

MCgluc is selected from the groups:



;

; and



where q is 1 to 8, and AA is an amino acid side chain;

where alkyl, alkylidiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclidiyl, heterocyclyl, heterocyclidiyl, heteroaryl, and heteroaryldiyl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH₃, -CH₂CH₃, -CH=CH₂, -C≡CH, -C≡CCH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH₂OH, -CH₂OCH₃, -CH₂CH₂OH, -C(CH₃)₂OH, -CH(OH)CH(CH₃)₂, -C(CH₃)₂CH₂OH, -CH₂CH₂SO₂CH₃, -CH₂OP(O)(OH)₂, -CH₂F, -CHF₂, -CF₃, -CH₂CF₃, -CH₂CHF₂, -CH(CH₃)CN, -C(CH₃)₂CN, -CH₂CN, -CH₂NH₂, -CH₂NHSO₂CH₃, -CH₂NHCH₃, -CH₂N(CH₃)₂, -CO₂H, -COCH₃, -CO₂CH₃, -CO₂C(CH₃)₃, -COCH(OH)CH₃, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -C(CH₃)₂CONH₂, -NH₂, -NHCH₃, -N(CH₃)₂, -NHCOCH₃, -

$\text{N}(\text{CH}_3)\text{COCH}_3$, $-\text{NHS}(\text{O})_2\text{CH}_3$, $-\text{N}(\text{CH}_3)\text{C}(\text{CH}_3)_2\text{CONH}_2$, $-\text{N}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{CH}_3$, $-\text{NO}_2$, $=\text{O}$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, $-\text{O}(\text{CH}_2\text{CH}_2\text{O})_n-(\text{CH}_2)_m\text{CO}_2\text{H}$, $-\text{O}(\text{CH}_2\text{CH}_2\text{O})_n\text{H}$, $-\text{OP}(\text{O})(\text{OH})_2$, $-\text{S}(\text{O})_2\text{N}(\text{CH}_3)_2$, $-\text{SCH}_3$, $-\text{S}(\text{O})_2\text{CH}_3$, and $-\text{S}(\text{O})_3\text{H}$.

2. The immunoconjugate of claim 1 wherein the antibody is an antibody construct that has an antigen binding domain that binds PD-L1.

3. The immunoconjugate of claim 2 wherein the antibody is selected from the group consisting of atezolizumab, durvalumab, and avelumab, or a biosimilar or a biobetter thereof.

4. The immunoconjugate of claim 1 wherein the antibody is an antibody construct that has an antigen binding domain that binds HER2.

5. The immunoconjugate of claim 4 wherein the antibody is selected from the group consisting of trastuzumab and pertuzumab, or a biosimilar or a biobetter thereof.


6. The immunoconjugate of claim 1 wherein the antibody is an antibody construct that has an antigen binding domain that binds CEA.

7. The immunoconjugate of claim 6 wherein the antibody is labetuzumab, or a biosimilar or a biobetter thereof.

8. The immunoconjugate of any one of claims 1 to 7 wherein y is 0.

9. The immunoconjugate of any one of claims 1 to 7 wherein y is 1.


10. The immunoconjugate of any one of claims 1 to 7 wherein PEP has the formula:




wherein AA_1 and AA_2 are independently selected from a side chain of a naturally-occurring amino acid.

11. The immunoconjugate of claim 10 wherein AA_1 or AA_2 with an adjacent nitrogen atom form a 5-membered ring proline amino acid.

12. The immunoconjugate of claim 11 wherein PEP has the formula:



13. The immunoconjugate of any one of claims 1 to 7 wherein MCgluc has the formula:



14. The immunoconjugate of claim 10 wherein AA₁ and AA₂ are independently selected from H, -CH₃, -CH(CH₃)₂, -CH₂(C₆H₅), -CH₂CH₂CH₂CH₂NH₂, -CH₂CH₂CH₂NHC(NH)NH₂, -CHCH(CH₃)CH₃, -CH₂SO₃H, and -CH₂CH₂CH₂NHC(O)NH₂.

15. The immunoconjugate of claim 10 wherein AA₁ is -CH(CH₃)₂, and AA₂ is -CH₂CH₂CH₂NHC(O)NH₂.

16. The immunoconjugate of any one of claims 1 to 7 wherein X¹ is a bond, and R¹ is H.

17. The immunoconjugate of any one of claims 1 to 7 wherein X² is a bond, and R² is C₁-C₈ alkyl.

18. The immunoconjugate of any one of claims 1 to 7 wherein X² and X³ are each a bond, and R² and R³ are independently selected from C₁-C₈ alkyl, -O-(C₁-C₁₂ alkyl), -(C₁-C₁₂ alkyldiyl)-OR⁵, -(C₁-C₈ alkyldiyl)-N(R⁵)CO₂R⁵, and -O-(C₁-C₁₂ alkyl)-N(R⁵)CO₂R⁵.


19. The immunoconjugate of claim 18 wherein R² and R³ are each independently selected from -CH₂CH₂CH₃, -OCH₂CH₃, -CH₂CH₂CF₃, and -CH₂CH₂CH₂OH.

20. The immunoconjugate of claim 18 wherein R² is C₁-C₈ alkyl and R³ is -(C₁-C₈ alkyldiyl)-N(R⁵)CO₂R⁴.

21. The immunoconjugate of claim 20 wherein R² is -CH₂CH₂CH₃ and R³ is -CH₂CH₂CH₂NHCO₂(*t*-Bu).

22. The immunoconjugate of claim 23 wherein R² and R³ are each -CH₂CH₂CH₃.

23. The immunoconjugate of claim 17 wherein X³-R³ is selected from the group consisting of:



24. The immunoconjugate of any one of claims 1 to 7 wherein Het is a 5- or 6-membered monocyclic heteroaryldiyl selected from the group consisting of pyridyldiyl, imidazolyldiyl, pyrimidinyl, pyrazolyldiyl, triazolyldiyl, pyrazinyldiyl, tetrazolyldiyl, furyldiyl, thienyldiyl, isoxazolyldiyl, thiazolyldiyl, oxadiazolyldiyl, oxazolyldiyl, isothiazolyldiyl, and pyrrolyldiyl.




25. The immunoconjugate of any one of claims 1 to 7 wherein Het is a 5- or 6-membered monocyclic heterocyclyldiyl selected from the group consisting of morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, thiomorpholinyl, and S-dioxothiomorpholinyl.


26. The immunoconjugate of any one of claims 1 to 7 wherein Het is 1,6-naphthyridyl or 1,6-naphthyridyl.

27. The immunoconjugate of any one of claims 1 to 7 wherein L is selected from the group consisting of:


$-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-(\text{C}_1-\text{C}_{20} \text{ heteroarylidiyl})-\text{CH}_2\text{O}-(\text{PEG})-\text{C}(=\text{O})-$
 $(\text{MCgluc})-\text{NR}^5(\text{C}_1-\text{C}_{12} \text{ alkylidiyl})\text{NR}^5\text{C}(=\text{O})-(\text{C}_2-\text{C}_5$
 $\text{monoheterocyclidiyl})-$;
 $-\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-\text{NR}^5(\text{C}_1-\text{C}_{12} \text{ alkylidiyl})-$;
 $-\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-\text{NR}^5(\text{C}_1-\text{C}_{12} \text{ alkylidiyl})\text{NR}^5\text{C}(=\text{O})-(\text{C}_2-\text{C}_5$
 $\text{monoheterocyclidiyl})-$;
 $-\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-(\text{PEP})-\text{NR}^5(\text{C}_1-\text{C}_{12} \text{ alkylidiyl})-$;
 $-\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-(\text{PEP})-\text{NR}^5(\text{C}_1-\text{C}_{12} \text{ alkylidiyl})\text{NR}^5\text{C}(=\text{O})-(\text{C}_2-\text{C}_5$
 $\text{monoheterocyclidiyl})-$; and
 $-(\text{succinimidy})-(\text{CH}_2)_m-\text{C}(=\text{O})-(\text{PEP})-\text{NR}^5(\text{C}_1-\text{C}_{12} \text{ alkylidiyl})\text{NR}^5\text{C}(=\text{O})-(\text{C}_2-$
 $\text{C}_5 \text{ monoheterocyclidiyl})-$.

28. The immunoconjugate of any one of claims 1 to 7 selected from Formulae Ia-d:





29. An 8-amido-2-aminobenzazepine-linker compound of Formula II:



wherein

y is 0 or 1;

Het is selected from the group consisting of heterocyclyl, heterocyclldiyl, heteroaryl, and heteroaryldiyl;

R^a is H or forms Het with the nitrogen atom it is bound to;

R¹, R², R³, and R⁴ are independently selected from the group consisting of H, C₁-C₁₂ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₂ carbocyclyl, C₆-C₂₀ aryl, C₂-C₉ heterocyclyl, and C₁-C₂₀ heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally substituted with one or more groups selected from:

- (C₁-C₁₂ alkylldiyl)-N(R⁵)-*;
- (C₁-C₁₂ alkylldiyl)-N(R⁵)₂;
- (C₁-C₁₂ alkylldiyl)-OR⁵;
- (C₃-C₁₂ carbocyclyl);
- (C₃-C₁₂ carbocyclyl)-*;
- (C₃-C₁₂ carbocyclyl)-(C₁-C₁₂ alkylldiyl)-NR⁵-*;
- (C₃-C₁₂ carbocyclyl)-(C₁-C₁₂ alkylldiyl)-N(R⁵)₂;
- (C₃-C₁₂ carbocyclyl)-NR⁵-C(=NR⁵)NR⁵-*;
- (C₆-C₂₀ aryl);
- (C₆-C₂₀ aryl)-*;
- (C₆-C₂₀ arylldiyl)-N(R⁵)-*;
- (C₆-C₂₀ arylldiyl)-(C₁-C₁₂ alkylldiyl)-N(R⁵)-*;

$-(C_6-C_{20} \text{ arylldiyl})-(C_1-C_{12} \text{ alkylldiyl})-(C_2-C_{20} \text{ heterocyclyldiyl})-^*$;
 $-(C_6-C_{20} \text{ arylldiyl})-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)_2$;
 $-(C_6-C_{20} \text{ arylldiyl})-(C_1-C_{12} \text{ alkylldiyl})-NR^5-C(=NR^{5a})N(R^5)-^*$;
 $-(C_2-C_{20} \text{ heterocyclyl})$;
 $-(C_2-C_{20} \text{ heterocyclyl})-^*$;
 $-(C_2-C_9 \text{ heterocyclyl})-(C_1-C_{12} \text{ alkylldiyl})-NR^5-^*$;
 $-(C_2-C_9 \text{ heterocyclyl})-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)_2$;
 $-(C_2-C_9 \text{ heterocyclyl})-NR^5-C(=NR^{5a})NR^5-^*$;
 $-(C_1-C_{20} \text{ heteroaryl})$;
 $-(C_1-C_{20} \text{ heteroaryl})-^*$;
 $-(C_1-C_{20} \text{ heteroaryl})-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)-^*$;
 $-(C_1-C_{20} \text{ heteroaryl})-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)_2$;
 $-(C_1-C_{20} \text{ heteroaryl})-NR^5-C(=NR^{5a})N(R^5)-^*$;
 $-C(=O)-^*$;
 $-C(=O)-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)-^*$;
 $-C(=O)-(C_2-C_{20} \text{ heterocyclyldiyl})-^*$;
 $-C(=O)N(R^5)_2$;
 $-C(=O)N(R^5)-^*$;
 $-C(=O)N(R^5)-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)C(=O)R^5$;
 $-C(=O)N(R^5)-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)C(=O)N(R^5)_2$;
 $-C(=O)NR^5-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)CO_2R^5$;
 $-C(=O)NR^5-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)C(=NR^{5a})N(R^5)_2$;
 $-C(=O)NR^5-(C_1-C_{12} \text{ alkylldiyl})-NR^5C(=NR^{5a})R^5$;
 $-C(=O)NR^5-(C_1-C_8 \text{ alkylldiyl})-NR^5(C_2-C_5 \text{ heteroaryl})$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroarylldiyl})-N(R^5)-^*$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroarylldiyl})-^*$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroarylldiyl})-(C_1-C_{12} \text{ alkylldiyl})-N(R^5)_2$;
 $-C(=O)NR^5-(C_1-C_{20} \text{ heteroarylldiyl})-(C_2-C_{20} \text{ heterocyclyldiyl})-C(=O)NR^5-(C_1-C_{12} \text{ alkylldiyl})-NR^5-^*$;
 $-N(R^5)_2$;
 $-N(R^5)-^*$;
 $-N(R^5)C(=O)R^5$;
 $-N(R^5)C(=O)-^*$

$-\text{N}(\text{R}^5)\text{C}(=\text{O})\text{N}(\text{R}^5)_2$;
 $-\text{N}(\text{R}^5)\text{C}(=\text{O})\text{N}(\text{R}^5)-*$;
 $-\text{N}(\text{R}^5)\text{CO}_2\text{R}^5$;
 $-\text{NR}^5\text{C}(=\text{NR}^{5a})\text{N}(\text{R}^5)_2$;
 $-\text{NR}^5\text{C}(=\text{NR}^{5a})\text{N}(\text{R}^5)-*$;
 $-\text{NR}^5\text{C}(=\text{NR}^{5a})\text{R}^5$;
 $-\text{N}(\text{R}^5)-(\text{C}_2-\text{C}_5 \text{ heteroaryl})$;
 $-\text{O}-(\text{C}_1-\text{C}_{12} \text{ alkyl})$;
 $-\text{O}-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{N}(\text{R}^5)_2$;
 $-\text{O}-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{N}(\text{R}^5)-*$;
 $-\text{S}(=\text{O})_2-(\text{C}_2-\text{C}_{20} \text{ heterocyclyldiyl})-*$;
 $-\text{S}(=\text{O})_2-(\text{C}_2-\text{C}_{20} \text{ heterocyclyldiyl})-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{N}(\text{R}^5)_2$;
 $-\text{S}(=\text{O})_2-(\text{C}_2-\text{C}_{20} \text{ heterocyclyldiyl})-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{NR}^5-*$; and
 $-\text{S}(=\text{O})_2-(\text{C}_2-\text{C}_{20} \text{ heterocyclyldiyl})-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{OH}$;
 or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1 , X^2 , X^3 , and X^4 are independently selected from the group consisting of a bond, $\text{C}(=\text{O})$, $\text{C}(=\text{O})\text{N}(\text{R}^5)$, O , $\text{N}(\text{R}^5)$, S , $\text{S}(\text{O})_2$, and $\text{S}(\text{O})_2\text{N}(\text{R}^5)$;


R^5 is selected from the group consisting of H , C_6-C_{20} aryl, C_6-C_{20} arylidyl, C_1-C_{12} alkyl, and C_1-C_{12} alkylidyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of C_6-C_{20} aryl and C_1-C_{20} heteroaryl;

where the asterisk * indicates the attachment site of L , and where one of R^1 , R^2 , R^3 and R^4 is attached to L ;


L is the linker selected from the group consisting of:

$\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-(\text{PEP})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{NR}^5-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{NR}^5-(\text{PEG})-\text{C}(=\text{O})-(\text{PEP})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{N}^+(\text{R}^5)_2-(\text{PEG})-\text{C}(=\text{O})-(\text{PEP})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{NR}^5\text{CH}(\text{AA}_1)\text{C}(=\text{O})-(\text{PEG})-\text{C}(=\text{O})-(\text{PEP})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{SS}-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{OC}(=\text{O})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-\text{SS}-(\text{C}_1-\text{C}_{12} \text{ alkylidyl})-\text{C}(=\text{O})-$;
 $\text{Q}-\text{C}(=\text{O})-(\text{PEG})-$;




where PEG has the formula: $-(CH_2CH_2O)_n-(CH_2)_m-$; m is an integer from 1 to 5, and n is an integer from 2 to 50;

PEP has the formula:




where AA₁ and AA₂ are independently selected from an amino acid side chain, or AA₁ or AA₂ and an adjacent nitrogen atom form a 5-membered ring proline amino acid, and the wavy line indicates a point of attachment and;

R⁶ is selected from the group consisting of C₆-C₂₀ arylidiyl and C₁-C₂₀ heteroaryldiyl, substituted with $-CH_2O-C(=O)-$ and optionally with:




; and


MCgluc is selected from the groups:



;



; and



where q is 1 to 8, and AA is an amino acid side chain; and

Q is selected from the group consisting of N-hydroxysuccinimidyl, N-hydroxysulfosuccinimidyl, maleimide, and phenoxy substituted with one or more groups independently selected from F, Cl, NO₂, and SO₃⁻;


where alkyl, alkylidiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH₃, -CH₂CH₃, -CH=CH₂, -C≡CH, -C≡CCH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH(CH₃)₂, -CH₂OH, -CH₂OCH₃, -CH₂CH₂OH, -C(CH₃)₂OH, -CH(OH)CH(CH₃)₂, -C(CH₃)₂CH₂OH, -CH₂CH₂SO₂CH₃, -CH₂OP(O)(OH)₂, -CH₂F, -CHF₂, -CF₃, -CH₂CF₃, -CH₂CHF₂, -CH(CH₃)CN, -C(CH₃)₂CN, -CH₂CN, -CH₂NH₂, -CH₂NHSO₂CH₃, -CH₂NHCH₃, -CH₂N(CH₃)₂, -CO₂H, -COCH₃, -CO₂CH₃, -CO₂C(CH₃)₃, -COCH(OH)CH₃, -CONH₂, -

CONHCH₃, -CON(CH₃)₂, -C(CH₃)₂CONH₂, -NH₂, -NHCH₃, -N(CH₃)₂, -NHCOCH₃, -N(CH₃)COCH₃, -NHS(O)₂CH₃, -N(CH₃)C(CH₃)₂CONH₂, -N(CH₃)CH₂CH₂S(O)₂CH₃, -NO₂, =O, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂OCH₃, -OCH₂CH₂OH, -OCH₂CH₂N(CH₃)₂, -O(CH₂CH₂O)_n-(CH₂)_mCO₂H, -O(CH₂CH₂O)_nH, -OP(O)(OH)₂, -S(O)₂N(CH₃)₂, -SCH₃, -S(O)₂CH₃, and -S(O)₃H.

30. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein y is 0.

31. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein y is 1.


32. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein PEP has the formula:




wherein AA₁ and AA₂ are independently selected from a side chain of a naturally-occurring amino acid.

33. The 8-amido-2-aminobenzazepine-linker compound of claim 32 wherein AA₁ or AA₂ with an adjacent nitrogen atom form a 5-membered ring to form a proline amino acid.


34. The 8-amido-2-aminobenzazepine-linker compound of claim 33 wherein PEP has the formula:



35. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein MCgluc has the formula:



36. The 8-amido-2-aminobenzazepine-linker compound of claim 32 wherein AA₁ and AA₂ are independently selected from H, -CH₃, -CH(CH₃)₂, -CH₂(C₆H₅), -CH₂CH₂CH₂CH₂NH₂, -CH₂CH₂CH₂NHC(NH)NH₂, -CHCH(CH₃)CH₃, -CH₂SO₃H, and -CH₂CH₂CH₂NHC(O)NH₂.
37. The 8-amido-2-aminobenzazepine-linker compound of claim 32 wherein AA₁ is -CH(CH₃)₂, and AA₂ is -CH₂CH₂CH₂NHC(O)NH₂.
38. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein X¹ is a bond, and R¹ is H.
39. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein X² is a bond, and R² is C₁-C₈ alkyl.
40. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein X² and X³ are each a bond, and R² and R³ are independently selected from C₁-C₈ alkyl, -O-(C₁-C₁₂ alkyl), -(C₁-C₁₂ alkyldiyl)-OR⁵, -(C₁-C₈ alkyldiyl)-N(R⁵)CO₂R⁵, and -O-(C₁-C₁₂ alkyl)-N(R⁵)CO₂R⁵.
41. The 8-amido-2-aminobenzazepine-linker compound of claim 40 wherein R² and R³ are each independently selected from -CH₂CH₂CH₃, -OCH₂CH₃, -CH₂CH₂CF₃, and -CH₂CH₂CH₂OH.
42. The 8-amido-2-aminobenzazepine-linker compound of claim 40 wherein R² is C₁-C₈ alkyl and R³ is -(C₁-C₈ alkyldiyl)-N(R⁵)CO₂R⁴.
43. The 8-amido-2-aminobenzazepine-linker compound of claim 42 wherein R² is -CH₂CH₂CH₃ and R³ is -CH₂CH₂CH₂NHCO₂(*t*-Bu).
44. The 8-amido-2-aminobenzazepine-linker compound of claim 40 wherein R² and R³ are each -CH₂CH₂CH₃.
45. The 5-amino-pyrazoloazepine-linker compound of claim 39 wherein X³-R³ is selected from the group consisting of:




46. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein Het is a 5- or 6-membered monocyclic heteroarylidiyl selected from the group consisting of pyridyldiyl, imidazolylidiyl, pyrimidinylidiyl, pyrazolylidiyl, triazolylidiyl, pyrazinylidiyl, tetrazolylidiyl, furyldiyl, thienyldiyl, isoxazolylidiyl, thiazolylidiyl, oxadiazolylidiyl, oxazolylidiyl, isothiazolylidiyl, and pyrrolyldiyl.


47. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein Het is a 5- or 6-membered monocyclic heterocyclyldiyl selected from the group consisting of morpholinyldiyl, piperidinyldiyl, piperazinyldiyl, pyrrolidinyldiyl, dioxanyldiyl, thiomorpholinyldiyl, and S-dioxothiomorpholinyldiyl.

48. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein Het is 1,6-naphthyridyl or 1,6-naphthyridyl.

49. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein L is selected from the group consisting of:




50. The 8-amido-2-aminobenzazepine-linker compound of claim 29 wherein Q is selected from:






51. The aminoquinoline-linker compound of claim 29 wherein Q is phenoxy substituted with one or more F.

52. The aminoquinoline-linker compound of claim 51 wherein Q is 2,3,5,6-tetrafluorophenoxy.

53. The 8-amido-2-aminobenzazepine-linker compound of claim 29 selected from Formulae IIa-d:





54. The 8-amido-2-aminobenzazepine-linker compound of claim 29 selected from Table 2a.
55. The 8-amido-2-aminobenzazepine-linker compound of claim 29 selected from Table 2b.
56. A method for treating cancer comprising administering a therapeutically effective amount of an immunoconjugate according to any one of claims 1 to 7, to a patient in need thereof.
57. The method of claim 56, wherein the cancer is susceptible to a pro-inflammatory response induced by TLR7 and/or TLR8 agonism.
58. The method of claim 56, wherein the cancer is a PD-L1-expressing cancer.
59. The method of claim 56, wherein the cancer is a HER2-expressing cancer.
60. The method of claim 56 wherein the cancer is a CEA-expressing cancer.
61. The method of claim 56 wherein the cancer is a Caprin-1-expressing cancer.
62. The method of any one of claims 56-61, wherein the cancer is selected from bladder cancer, urinary tract cancer, urothelial carcinoma, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer.

63. The method of claim 62, wherein the breast cancer is triple-negative breast cancer.
64. The method of claim 62, wherein the Merkel cell carcinoma cancer is metastatic Merkel cell carcinoma.
65. The method of claim 62, wherein the gastric cancer is HER2 overexpressing gastric cancer.
66. The method of claim 62, wherein the cancer is gastroesophageal junction adenocarcinoma.
67. Use of an immunoconjugate according to any one of claims 1 to 7 for treating cancer.
68. A method of preparing an immunoconjugate of Formula I of claim 1 wherein an 8-amido-2-aminobenzazepine-linker compound of Formula II of claim 29 is conjugated with the antibody.
69. The method of claim 68 wherein the 8-amido-2-aminobenzazepine-linker compound is selected from Table 2a or Table 2b.